DELTA-FLY-PHARMA
2.2.2024 07:16:29 CET | Business Wire | Press release
We are excited to share our latest development status.
As presented at 2022 ASCO Annual Meeting on June 6, 2022, DFP-14323 in combination with afatinib (20 mg/day) in stage III/IV non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutation positive in a Phase II clinical trial, has demonstrated fascinating longer median progression-free survival (mPFS; 23.1 months).
Subsequently, based on these results, we have been in negotiation with the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan with the aim of submitting a conditional approval application, resulting in our decision to conduct a Phase III clinical trial (superiority study) of DFP-14323 in combination with afatinib (20 mg/day) versus afatinib (40 mg/day) alone in stage III/IV non-small cell lung cancer patients with uncommon EGFR mutation positive based on the PMDA's recommendation.
And finally, we are pleased to announce that the submission of the protocol for the Phase III study to the PMDA has been approved and are ready to initiate the study.
This Phase III clinical trial will be conducted at 30 sites in Japan and if the superiority of the add-on effect of DFP-14323 on progression-free survival (PFS) as primary endpoint, is confirmed in this trial, we believe that DFP-14323 will be a novel cancer immunotherapy drug with highly beneficial for patients and their families, as it is orally available, safe, and economical.
Furthermore, if non-inferiority to osimertinib (80 mg/day) can be confirmed in a comparative study, a huger market can be expected.
We intend to continue negotiations for out-licensing opportunities with pharmaceutical companies for the territory outside Japan.
Please find out the innovation for the miserable cancer patients by Delta-Fly Pharma Inc. (TOKYO:4598) and contact with us.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240201128942/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Dalton Maag Launches Radically Simplified Font Licensing Model2.3.2026 14:00:00 CET | Press release
Dalton Maag, the independent typeface design studio, today launched a comprehensive overhaul of its retail font licensing structure, consolidating complex rights into four licence types. The new model aims to eliminate ‘licence anxiety’ for creatives and businesses by replacing narrow, technical restrictions with broad, generous permissions. For many years, the font industry has been defined by confusing bundling practices and legal traps. Whether a licence is too granular – forcing buyers to make too many small decisions – or too restrictive – blocking reasonable use – the result is the same: obstacles that hinder rather than enable creativity and communication. Dalton Maag’s new licensing structure directly addresses these challenges. “We’ve seen font licensing become harder to understand and easier to get wrong,” said Lukas Paltram, Executive Creative Director at Dalton Maag. “Our goal was to make licensing as simple as it can be without sacrificing fairness. Designers should be abl
SBC Medical Appoints Sheng-FU Hsiao as CTOLeveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure2.3.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the appointment of Sheng-FU Hsiao as Chief Technology Officer (CTO), effective March 1, 2026. This appointment aligns with the Company’s 2026 management strategy, "Sophistication of Management Structure through AI and DX," and strengthens its leadership team to accelerate technological transformation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260302064873/en/ SBC Medical Appoints Sheng-FU Hsiao as CTO Leveraging Medical Big Data from 283 Global Locations and 6.63 Million Annual Patient Visits to Build a Scalable, AI-Driven Medical Management Infrastructure SBC Medical is transitioning from a traditional labor-intensive management model to an AI-driven infrastructure to address structural challenges in the m
SIMO Expands Carrier Enablement Strategy to Power Resilient, Multi-Network Enterprise Fixed Wireless Access Deployments2.3.2026 13:00:00 CET | Press release
xSIM orchestration delivers cross-network performance and unified global FWA deployment. SIMO, a leader in innovative mobile connectivity solutions, today announced the expansion of its carrier enablement strategy to power resilient, multi-network enterprise Fixed Wireless Access (FWA) deployments for both primary and backup applications. SIMO will showcase its evolution to a carrier enablement platform powering enterprise-grade FWA at Mobile World Congress 2026, in the MediaTek booth (Hall 3, Booth 3D10). “The future of enterprise FWA is not single-network, it is intelligently orchestrated multi-network connectivity,” said Eric Plam, chief revenue officer at SIMO. “By combining AI-driven local network selection with centralized global control, carriers can deliver resilient connectivity at scale while unlocking recurring managed service revenue.” Through SIMO xSIM orchestration operating at both the device firmware layer and the cloud, SIMO enables intelligent multi-network selection,
Venture Global Announces LNG Purchase Agreement with Trafigura2.3.2026 12:02:00 CET | Press release
New 5-year agreement offers flexibility and diversification to LNG portfolio Today, Venture Global, Inc. (NYSE: VG) and Trafigura announced the execution of a new, binding agreement for the purchase of approximately 0.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for five years commencing in 2026. This mid-term agreement offers greater flexibility to customers in the global LNG market and provides greater diversification for Venture Global’s LNG portfolio. “Trafigura is a global leader in LNG trading, and we are pleased to execute this mid-term LNG supply agreement with them to provide the market with flexible and reliable U.S. LNG,” said Venture Global CEO Mike Sabel. “Global energy demand is stronger than ever, and this is an important step in executing our strategy of adding more mid-term agreements, which will diversify the tenor of our LNG portfolio. Venture Global looks forward to helping ensure the world remains well-supplied in the sh
“AI Realized Through Display” … Samsung Display Showcases AI-Optimized OLED Technologies at MWC262.3.2026 10:58:00 CET | Press release
Introducing “Flex Magic Pixel™,” a panel-integrated privacy technology enabled by low-power, high-brightness LEAD™… Essential smartphone privacy for the AI era’s surge in personalized data usage “Thinner and tougher”… Foldable OLED durability proven with a golf putting challenge “Create your own K-pop concert”… MR experience equipped with 5,000 PPI RGB OLEDoS draws major attention New concept “edge devices” incorporating Samsung Display OLED’s unique free-form, low-power and high-resolution technologies unveiled – including the companion robot concept “Mini PetBot” and the interior décor item “AI Toy House” Spain’s Park Güell tile mosaics recreated through displays using 6.8-inch OLED and 27-inch QD-OLED, highlighting high color reproduction and bezel-less technology Eric Kim, Executive Vice President and Head of Mobile Strategic Marketing: “In the AI era, displays will evolve from simple viewing screens into intelligent interfaces that understand and respond to users and their surroun
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom